Q2 21 beat was led by the robust demand for non-COVID products. However, given the faster adoption of vaccines, demand for COVID-19 tests has faded earlier than expected and thus management has trimmed its full-year sales outlook. Earnings are also expected to come in at the lower end of the guidance range and we won’t be surprised if talks resurface for the shake-up of the company’s board. However, the new $100m share buy-back programme reflects management’s confidence in its five strategic pil ....
